Home › Compare › UNPRF vs ABBV
UNPRF yields 1.97% · ABBV yields 3.09%● Live data
📍 ABBV pulled ahead of the other in Year 1
Combined, UNPRF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of UNPRF + ABBV for your $10,000?
Uniper SE operates as an energy company. It operates in three segments: European Generation, Global Commodities, and Russian Power Generation. The company owns and operates various power and heat generation facilities, including fossil fuel power plants, such as coal, gas, oil, and combined gas and steam; and hydroelectric, nuclear, biomass, photovoltaic, and wind power plants. It also markets energy services comprising fuel procurement, and engineering and asset management, as well as operational and maintenance services; and procures fuels, trades in emission allowances, and markets electricity. In addition, the company engages in the sale of individual power and natural gas to resellers, industrial customers, and power plant operators; energy trading activities; infrastructure investments and gas storage operations; fuel procurement for power plants; operation and management of the plants; and trade and sale of energy. Further, it trades in commodities, which comprise power, natural gas, liquefied natural gas, and coal and freight solutions; provides district heating and online gas dispatch services; operates gas storage and power-to-gas facilities in Germany, Austria, and the United Kingdom; and owns and operates marine fuel oils production facility in Fujairah. It operates in Germany, the United Kingdom, the Russian Federation, rest of Europe, and internationally. The company was founded in 2016 and is headquartered in Düsseldorf, Germany. Uniper SE is a subsidiary of Karemi Charge and Drive SE.
Full UNPRF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.